Stockreport

Could An Earlier-Than-Expected Approval Send This Biotech Into A Breakout? [Investor's Business Daily]

Global Blood Therapeutics, Inc.  (GBT) 
NASDAQ:AMEX Investor Relations: ir.globalbloodtx.com
PDF Related news 11/19/2019 Global Blood Therapeutic shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 68 to 81. Global Blood [Read more]